Drug Profile
Cabazitaxel - Starpharma
Alternative Names: CTX-SPL-9111; DEP CTX; DEP® CabazitaxelLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator Starpharma
- Class Amines; Antineoplastics; Benzene derivatives; Esters; Small molecules; Taxanes
- Mechanism of Action Tubulin inhibitors; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
- Preclinical Pancreatic cancer
- No development reported Breast cancer
Most Recent Events
- 18 Jan 2024 Efficacy and adverse events data from phase I/II trial for Solid tumours released by Starpharma
- 18 Oct 2023 Efficacy and adverse events data from phase I/II trial for Solid tumours released by Starpharma
- 31 Jul 2023 Starpharma completes phase I/II trial in Solid tumours (IV) in United Kingdom and Australia (EudraCT2017-003424-76)